Zolmitriptan Intranasal Spanlastics for Enhanced Migraine Treatment; Formulation Parameters Optimized via Quality by Design Approach

• Váldodahkkit: Asmaa Saleh (Dahkki), Maha Khalifa (Dahkki), Seham Shawky (Dahkki), Amjaad Bani-Ali (Dahkki), Heba Eassa (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: MDPI AG, 2021-05-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Zolmitriptan is a potent second-generation triptan prescribed for migraine attacks. It suffers low bioavailability (40%) after oral administration due to the hepatic first-pass metabolism. Spanlastics are surfactant-based elastic vesicular drug carrier systems. This study aimed to design and optimiz...